Anti-SARS-CoV-2 Antibody Responses in Patients With IBD Treated With Biologics: Are We Finding CLARITY?

Affiliations

¹ Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex, National Health Service Foundation Trust, West Sussex, United Kingdom; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.
² Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
³ Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal; Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
⁴ Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.

Comment

Thomas P Chapman et al. Gastroenterology. 2021 Dec.

. 2021 Dec;161(6):2057-2059.

doi: 10.1053/j.gastro.2021.09.019. Epub 2021 Sep 14.

¹ Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex, National Health Service Foundation Trust, West Sussex, United Kingdom; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.
² Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
³ Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal; Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
⁴ Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.

No abstract available

Comment on

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Gut. 2021 Oct;70(10):1884-1893. doi: 10.1136/gutjnl-2021-324789. Epub 2021 Apr 26. Gut. 2021. PMID: 33903149